269 related articles for article (PubMed ID: 15551031)
1. [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].
Ba-Ssalamah A; Happel B; Kettenbach J; Dirisamer A; Wrba F; Längle F; Schima W
Radiologe; 2004 Dec; 44(12):1170-84. PubMed ID: 15551031
[TBL] [Abstract][Full Text] [Related]
2. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
3. [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].
Stroszczynski C; Gaffke G; Gnauck M; Streitparth F; Wieners G; Lopez-Häninnen E
Radiologe; 2004 Dec; 44(12):1185-91. PubMed ID: 15549226
[TBL] [Abstract][Full Text] [Related]
4. Contrast agents for MR imaging of the liver.
Low RN
J Magn Reson Imaging; 1997; 7(1):56-67. PubMed ID: 9039594
[TBL] [Abstract][Full Text] [Related]
5. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
Burke C; Alexander Grant L; Goh V; Griffin N
Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
[TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
[TBL] [Abstract][Full Text] [Related]
7. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
Reimer P; Schneider G; Schima W
Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of biphasic spiral CT and MnDPDP-enhanced MRI in the detection and characterization of liver lesions].
Grimm J; Müller-Hülsbeck S; Blume J; Biederer J; Heller M
Rofo; 2001 Mar; 173(3):266-72. PubMed ID: 11293872
[TBL] [Abstract][Full Text] [Related]
9. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Kim MJ; Kim JH; Lim JS; Oh YT; Chung JJ; Choi JS; Lee WJ; Kim KW
J Magn Reson Imaging; 2004 Oct; 20(4):612-21. PubMed ID: 15390224
[TBL] [Abstract][Full Text] [Related]
10. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
11. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: initial observations.
Martin DR; Semelka RC; Chung JJ; Balci NC; Wilber K
Magn Reson Imaging; 2000 Oct; 18(8):955-63. PubMed ID: 11121698
[TBL] [Abstract][Full Text] [Related]
12. Contrast-enhanced MR imaging of the liver.
Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
[TBL] [Abstract][Full Text] [Related]
13. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
Ba-Ssalamah A; Schima W; Schmook MT; Linnau KF; Schibany N; Helbich T; Reimer P; Laengle F; Wrba F; Kurtaran A; Ryan M; Mann FA
AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
[TBL] [Abstract][Full Text] [Related]
14. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
15. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
Chung JJ; Kim MJ; Kim KW
J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
[TBL] [Abstract][Full Text] [Related]
16. Imaging liver metastases: review and update.
Kanematsu M; Kondo H; Goshima S; Kato H; Tsuge U; Hirose Y; Kim MJ; Moriyama N
Eur J Radiol; 2006 May; 58(2):217-28. PubMed ID: 16406434
[TBL] [Abstract][Full Text] [Related]
17. Comparison of gadolinium chelates with manganese-DPDP for liver lesion detection and characterization: preliminary results.
Kettritz U; Schlund JF; Wilbur K; Eisenberg LB; Semelka RC
Magn Reson Imaging; 1996; 14(10):1185-90. PubMed ID: 9065909
[TBL] [Abstract][Full Text] [Related]
18. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT.
Oudkerk M; Torres CG; Song B; König M; Grimm J; Fernandez-Cuadrado J; Op de Beeck B; Marquardt M; van Dijk P; de Groot JC
Radiology; 2002 May; 223(2):517-24. PubMed ID: 11997562
[TBL] [Abstract][Full Text] [Related]
19. [The clinical value of Mn-DPDP: a new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver].
Vogl TJ; Hamm B; Schnell B; Eibl-Eibesfeldt B; Steiner S; Lissner J
Rofo; 1991 Dec; 155(6):568-74. PubMed ID: 1764599
[TBL] [Abstract][Full Text] [Related]
20. Focal liver lesion detection and characterization with GD-EOB-DTPA.
Purysko AS; Remer EM; Veniero JC
Clin Radiol; 2011 Jul; 66(7):673-84. PubMed ID: 21524416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
